CYTK – Cytokinetics, Incorporated
CYTK — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
13.24
Margin Of Safety %
Put/Call OI Ratio
0.37
EPS Next Q Diff
0.08
EPS Last/This Y
0.11
EPS This/Next Y
1.68
Price
76.92
Target Price
104.7
Analyst Recom
1.3
Performance Q
12.72
Upside
-411.2%
Beta
0.41
Ticker: CYTK
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-24 | CYTK | 65.34 | 0.32 | 0.49 | 115115 |
| 2026-04-27 | CYTK | 61.63 | 0.32 | 10.06 | 115221 |
| 2026-04-28 | CYTK | 60.63 | 0.38 | 2.54 | 121250 |
| 2026-04-29 | CYTK | 59.57 | 0.39 | 0.32 | 122714 |
| 2026-04-30 | CYTK | 63.98 | 0.41 | 0.65 | 123731 |
| 2026-05-01 | CYTK | 63.36 | 0.41 | 0.21 | 125213 |
| 2026-05-04 | CYTK | 66.01 | 0.41 | 0.48 | 128528 |
| 2026-05-05 | CYTK | 76.95 | 0.41 | 0.68 | 132830 |
| 2026-05-06 | CYTK | 74.83 | 0.44 | 0.37 | 145827 |
| 2026-05-07 | CYTK | 74.28 | 0.45 | 0.36 | 151357 |
| 2026-05-08 | CYTK | 76.63 | 0.45 | 0.04 | 152922 |
| 2026-05-11 | CYTK | 74.84 | 0.46 | 0.13 | 149975 |
| 2026-05-12 | CYTK | 74.77 | 0.47 | 0.02 | 150520 |
| 2026-05-13 | CYTK | 77.22 | 0.45 | 0.59 | 153527 |
| 2026-05-14 | CYTK | 78.41 | 0.45 | 0.45 | 153207 |
| 2026-05-15 | CYTK | 75.85 | 0.44 | 0.06 | 152119 |
| 2026-05-18 | CYTK | 75.18 | 0.39 | 0.08 | 90335 |
| 2026-05-19 | CYTK | 76.46 | 0.39 | 0.43 | 90560 |
| 2026-05-20 | CYTK | 78.72 | 0.39 | 0.09 | 91334 |
| 2026-05-21 | CYTK | 78.07 | 0.38 | 0.04 | 93774 |
| 2026-05-22 | CYTK | 76.91 | 0.37 | 0.07 | 95749 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-24 | CYTK | 65.29 | -21.0 | -66.0 | -6.58 |
| 2026-04-27 | CYTK | 61.63 | -21.0 | -27.9 | -6.58 |
| 2026-04-28 | CYTK | 60.64 | -21.0 | -57.3 | -6.58 |
| 2026-04-30 | CYTK | 63.98 | -21.0 | -120.9 | -6.58 |
| 2026-05-01 | CYTK | 63.42 | -21.0 | -62.3 | -6.58 |
| 2026-05-04 | CYTK | 66.03 | -21.0 | -97.7 | -6.58 |
| 2026-05-05 | CYTK | 77.12 | -21.1 | -188.1 | -6.58 |
| 2026-05-06 | CYTK | 74.83 | -21.1 | -47.1 | -6.58 |
| 2026-05-07 | CYTK | 74.28 | -20.0 | -49.9 | -6.61 |
| 2026-05-08 | CYTK | 76.87 | -20.0 | -81.1 | -6.61 |
| 2026-05-11 | CYTK | 74.58 | -47.6 | -12.9 | -6.70 |
| 2026-05-12 | CYTK | 74.76 | -49.5 | -35.5 | -6.59 |
| 2026-05-13 | CYTK | 77.21 | -50.4 | -57.1 | -6.59 |
| 2026-05-14 | CYTK | 78.64 | -50.4 | -96.8 | -6.61 |
| 2026-05-15 | CYTK | 75.84 | -50.4 | -55.5 | -6.61 |
| 2026-05-18 | CYTK | 75.16 | -48.9 | -75.8 | -6.55 |
| 2026-05-19 | CYTK | 76.50 | -48.9 | -96.3 | -6.55 |
| 2026-05-20 | CYTK | 78.72 | -48.9 | -105.4 | -6.55 |
| 2026-05-21 | CYTK | 78.03 | -46.5 | -75.5 | -6.55 |
| 2026-05-22 | CYTK | 76.92 | -46.5 | -71.6 | -6.43 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-24 | CYTK | -10.29 | -2.09 | 13.17 |
| 2026-04-27 | CYTK | -10.29 | -1.79 | 12.47 |
| 2026-04-28 | CYTK | -7.65 | -1.79 | 12.47 |
| 2026-04-29 | CYTK | -7.82 | -1.79 | 12.47 |
| 2026-04-30 | CYTK | -8.15 | -1.79 | 12.47 |
| 2026-05-01 | CYTK | -8.04 | -1.79 | 12.47 |
| 2026-05-04 | CYTK | -8.39 | -1.92 | 12.47 |
| 2026-05-05 | CYTK | -8.34 | -1.92 | 12.47 |
| 2026-05-06 | CYTK | -9.70 | -1.92 | 12.47 |
| 2026-05-07 | CYTK | -9.70 | -1.92 | 12.47 |
| 2026-05-08 | CYTK | -9.61 | -1.92 | 12.34 |
| 2026-05-11 | CYTK | -9.61 | -2.38 | 12.34 |
| 2026-05-12 | CYTK | -9.66 | -2.38 | 13.18 |
| 2026-05-13 | CYTK | -9.55 | -2.38 | 13.18 |
| 2026-05-14 | CYTK | -9.55 | -2.38 | 13.18 |
| 2026-05-15 | CYTK | -9.71 | -2.38 | 13.18 |
| 2026-05-18 | CYTK | -9.71 | -1.22 | 13.24 |
| 2026-05-19 | CYTK | -8.56 | -1.22 | 13.24 |
| 2026-05-20 | CYTK | -8.53 | -1.22 | 13.24 |
| 2026-05-21 | CYTK | -8.53 | -1.22 | 13.24 |
| 2026-05-22 | CYTK | -8.53 | -1.22 | 13.24 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.67
Avg. EPS Est. Current Quarter
-1.64
Avg. EPS Est. Next Quarter
-1.59
Insider Transactions
-8.53
Institutional Transactions
-1.22
Beta
0.41
Average Sales Estimate Current Quarter
17
Average Sales Estimate Next Quarter
26
Fair Value
Quality Score
8
Growth Score
46
Sentiment Score
82
Actual DrawDown %
30.2
Max Drawdown 5-Year %
-72.4
Target Price
104.7
P/E
Forward P/E
PEG
P/S
90.48
P/B
P/Free Cash Flow
EPS
-6.84
Average EPS Est. Cur. Y
-6.43
EPS Next Y. (Est.)
-4.75
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-784.02
Relative Volume
0.4
Return on Equity vs Sector %
73.3
Return on Equity vs Industry %
88.9
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.14
EBIT Estimation
-71.6
◆
CYTK
Healthcare
$76.94
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
60.6
Range 1M
84%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
2.4%
EPS NY
28.1%
52W%
93.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+36.1% upside
Upside
+36.1%
Quality
8
Cytokinetics, IncorporatedSector: Healthcare
Industry: Biotechnology
Employees: 673
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK
Latest News
—
Caricamento notizie per CYTK…
stock quote shares CYTK – Cytokinetics, Incorporated Stock Price stock today
news today CYTK – Cytokinetics, Incorporated stock forecast ,stock prediction 2023 2024 2025
marketwatch CYTK – Cytokinetics, Incorporated yahoo finance google finance
stock history CYTK – Cytokinetics, Incorporated invest stock market
stock prices CYTK premarket after hours
ticker CYTK fair value insiders trading